Zaafir M. Dulloo

Zaafir M. Dulloo

Auto-generated profile, based on publicly available information

Zaafir M. Dulloo

Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
New agents are needed that selectively kill cancer cells without harming normal tissues. The TRAIL ligand and its receptors, DR5 and DR4, exhibit cancer-selective toxicity. TRAIL analogs or agonistic antibodies targeting these receptors are available but have not yet received FDA approval for cancer therapy. Small molecules for activating DR5 or DR4 independently of protein ligands may activate TRAIL receptors as a monotherapy or potentiate the efficacy of TRAIL analogs and agonistic antibodies. Previously described disulfide bond–disrupting agents activate DR5 by altering its disulfide bonding through inhibition of protein disulfide isomerases ERp44, AGR2, and PDIA1. Work presented in this article extends these findings by showing that disruption of single DR5 disulfide bonds causes high-level DR5 expression, disulfide-mediated clustering, and activation of caspase 8/caspase 3–mediated proapoptotic signaling. Recognition of the extracellular domain of DR5 by various antibodies is strongly influenced by the pattern of DR5 disulfide bonding, which has important implications for the use of agonistic DR5 antibodies for cancer therapy and as research tools. Importantly, other endoplasmic reticulum (ER) stressors, including thapsigargin and tunicamycin, also alter DR5 disulfide bonding in various cancer cell lines, and in some instances, DR5 mis-disulfide bonding is potentiated by overriding the integrated stress response (ISR) with inhibitors of the PERK kinase or the ISR inhibitor ISRIB. These observations indicate that the pattern of DR5 disulfide bonding functions as a sensor of ER stress and serves as an effector of proteotoxic stress by driving extrinsic apoptosis independently of extracellular ligands. Implications: Extreme ER stress triggers triage of transmembrane receptor production, whereby mitogenic receptors are downregulated and death receptors are simultaneously elevated.

8 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MLMary Law
Mary Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
BHBrian Hardy
Brian Hardy
AKAnia Kelegama
Ania Kelegama
RCReagan Clark
Reagan Clark
BLBrian K. Law
Brian K. Law
Protein Disulfide Isomerases (PDIs) are emerging targets in anticancer therapy, with several PDI inhibitors demonstrating anticancer efficacy in preclinical models. Research has largely focused on “canonical” PDIs, such as PDIA1, which contain CXXC active site motifs where C represents Cysteine. Canonical PDIs have well-studied, critical roles in forming, breaking, and exchanging/scrambling disulfide bonds during protein folding. In contrast, non-canonical PDIs, which harbor CXXS active site motifs, remain less well-studied despite their role as sensors or effectors of protein folding quality control during protein trafficking in the secretory pathway. Here, we provide a review of the literature relating to the non-canonical PDIs ERp44, AGR2, and AGR3, which have been identified as strong dependencies in specific cancer subtypes according to the DepMap database. The biological and biochemical functions of ERp44, AGR2, and AGR3 are discussed, highlighting the role of ERp44 in two mechanisms of protein folding quality control, AGR2 as a selective sensor of mucin protein misfolding, and a unique role for AGR3 in cilia. Finally, we discuss recent efforts to develop small molecule inhibitors of ERp44, AGR2, and AGR3 as tool compounds and experimental therapeutics.

21 May 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
ZDZaafir M. Dulloo
Zaafir M. Dulloo
IGIon Ghiviriga
Ion Ghiviriga
MLMary E. Law
Mary E. Law
SVSarvesh K. Verma
Sarvesh K. Verma
ASAbhisheak Sharma
Abhisheak Sharma
RCRonald Castellano
Ronald Castellano
Disulfide-bond Disrupting Agents (DDAs) are a class of cyclic thiosulfonates that have been shown to kill human epidermal growth factor receptor (HER) family-overexpressing breast cancer (BC) cells selectively and with no adverse side effects. Previous structure-activity relationships suggested a strong correlation between DDA lipophilicity and potency. In this study, we present the use of Cyclodextrins (CDs) as molecular excipients to address the possible solubilizing drawback of increasingly lipophilic DDAs in oral administrations. The formulation of tcyDTDO, a potent second-generation DDA, with Beta-Cyclodextrin (BCD) and 2-Hydroxypropyl-Beta-Cyclodextrin (HPB) was investigated. The choice of BCD as an optimal host over other CDs was guided by two in silico methods, namely: (1) Host cavity volume estimations using a computational modeling approach and (2) binding energy (BE) calculations from simulations of different complexation geometries. A solid-state inclusion complex (IC) between tcyDTDO and BCD was prepared by kneading. Characterization by ATR-FTIR revealed positioning of tcyDTDO inside the cavity of BCD. Phase-solubility plots were constructed using NMR spectroscopy to measure the concentrations of host and guest in solution; a powerful technique that has yet to be exploited in the context of host-guest chemistry. The AL-type plots obtained pointed to the formation of 1:1 complexes with both BCD and HPB. BCD formed a stronger complex with tcyDTDO (Ka of 4090 M-1) although the solubility of tcyDTDO was enhanced by only 3-fold from an intrinsic solubility of 1.58 mM. Contrastingly, HPB displayed a lower affinity for tcyDTDO (Ka of 81 M-1) but resulted in a remarkable 90-fold increase in solubility with tcyDTDO concentrations approaching 150 mM. Encapsulation of tcyDTDO in both cases did not hinder its anti-cancer activity as they retained cytotoxicity against MDA-MB-468 (EGFR+) BC cells in vitro. More striking was the superior pharmacokinetic profile and systemic exposure of tcyDTDO observed in male Sprague-Dawley rats when formulated with BCD as indicated by an area under the concentration vs. time curve (AUC0-24) of 3150 ± 381 ng·h/mL. This work suggests a correlation between Ka and in vivo pharmacokinetics of DDAs following their complexation with CDs and provides an ameliorated approach for their oral administration in future animal studies.

15 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MLMary Law
Mary Law
ZDZaafir Dulloo
Zaafir Dulloo
BHBrian Hardy
Brian Hardy
AKAnia Kelegama
Ania Kelegama
RCReagan Clark
Reagan Clark
BLBrian K. Law
Brian K. Law
Protein Disulfide Isomerases (PDIs) are emerging targets in anticancer therapy, with several PDI inhibitors demonstrating anticancer efficacy in preclinical models. Research has largely focused on “canonical” PDIs, such as PDIA1, which contain CXXC active site motifs where C represents Cysteine. Canonical PDIs have well-studied, critical roles in forming, breaking, and exchanging/scrambling disulfide bonds during protein folding. In contrast, non-canonical PDIs, which harbor CXXS active site motifs, remain less well-studied despite their role as sensors or effectors of protein folding quality control during protein trafficking in the secretory pathway. Here, we provide a review of the literature relating to the non-canonical PDIs ERp44, AGR2, and AGR3, which have been identified as strong dependencies in specific cancer subtypes according to the DepMap database. The biological and biochemical functions of ERp44, AGR2, and AGR3 are discussed, highlighting the role of ERp44 in two mechanisms of protein folding quality control, AGR2 as a selective sensor of mucin protein misfolding, and a unique role for AGR3 in cilia. Finally, we discuss recent efforts to develop small molecule inhibitors of ERp44, AGR2, and AGR3 as tool compounds and experimental therapeutics.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Figure S2. Neither CDCP1 overexpression, or inhibition of eEF2 kinase influence DDA induction of DR5 upregulation, DR4/5 oligomerization, or Caspase 8 cleavage.

2 July 2025
Verified
Other
Open access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
Supplementary Figure S1. DDAs upregulate DR5 and TNFR1 with minimal effect on other Death Receptors tested. Immunoblot analysis of the indicated cell lines treated for 24 h with the specified dMtcyDTDO concentrations and analyzed by immunoblot under non-reducing conditions.